Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for that explanation as it's not the profits that I am after also. Just trying to gain more shares as the MM allows me to.
Could you explain what you mean by exercising them for shares? It's what I wanted to do but didn't fully understand so I just sold them with 7 days left before expiration.
Im not a stats person but do understand that what Anavex released so far isn't the whole story of the drug. It is just playing with dosage and seeing what happens. Once its optimized and everyone is on the same amount, the real Anavex plotting should look a lot better than what those trials were.
aka: Let the whole A-273 trial run and see how it looks THEN, rather than think that what we have now is the best it can do.
In the mean time, just came back from Hawaii Island and thought some of you never saw a black sand beach before so.......
Black Sand Beach of Punaluu
Fictional Fantasy. = )
Consider we are a football team(Anavex). Would it be correct to say we are on our own 30 yard line with 70 yards to go? We are a long ways away from a touchdown(approval and accurate pps), but anything is possible especially when you have Tom Brady(Missling) on our team. Even coming back from 25 points(little below $2.50) and having all the big dogs(BP) hate on you.
Sorry, I'm a Titan fan. Gotta support my fellow island brother (Mariota)
Figured it out. The site added the three 0's for a total of 1535000 when it should have just been 1535 as the value.
It's why I'd rather have a takeover of say 1:1 or 1:2. If not, I'd just flip it and buy the new owner. It's the dividends I'd look forward to rather than selling the stock.
Wonder if you still think the same today. Just curious as you helped a lot of eyes discover Anavex a short 1.5 - 2 years ago.
Certainly gave me something to throw part of my 401 at. = )
Nice to see our Instys lining up.
So far we have 7,139,430 shares held by 59 tutes. Thats not including the shares Missling and Co. has.
Did a quick spreadsheet add of what was available at fintel as of 5 minutes ago.
Good read as far as our orphan drug for frontotemporal dementia
February 13, 2017
LINK
Link identified between nerve cell proteins and middle-age onset dementia
Fused in sarcoma (FUS) and its binding partner proline- and glutamine-rich (SFPQ) regulates Mapt splicing, resulting balanced ratio of tau isoforms. Loss of interaction between FUS and SFPQ alters Mapt splicing, and subsequently increases …more
Nagoya University-led research identifies role for neuronal protein interaction in preventing frontotemporal lobar degeneration, a dementia that starts in middle age.
Frontotemporal lobar degeneration (FTLD) is a type of dementia characterized by personality changes, language dysfunction, and abnormal behavior. It has an earlier onset than Alzheimer's disease, and is associated with a buildup of the tau protein in affected nerve cells (neurons).
Nagoya University-led Japanese research has now revealed that loss of the interaction between two RNA binding proteins changes the expression ratio of different forms of tau protein, producing the FTLD phenotype in mice, and that this could be rescued by rebalancing the tau ratio. The study was reported in Cell Reports.
The RNA binding protein FUS is linked to both familial and sporadic FTLD/ALS. The researchers investigated other proteins that bind the FUS complex within the nucleus and found another RNA metabolism regulator, SFPQ, to be key to the complex formation.
Both FUS and SFPQ control the process known as alternative splicing by which exons of a gene are joined to other exons or skipped altogether to produce different messenger RNAs and, consequently, different versions (isoforms) of the same protein. FUS/SFPQ-regulated alternative splicing of the Mapt gene at exon 10 produces two different tau isoforms (4R-T and 3R-T) that are usually balanced. However, the team showed that FUS or SFPQ silencing resulted in an excess of 4R-T over 3R-T.
The researchers generated mice lacking expression of FUS or SFPQ in a region of their brain important for memory and spatial navigation; the hippocampus. These mice were observed to have abnormal behaviors that resembled those of FTLD.
"They also had a reduced hippocampal volume, loss of neuronal cells, and less nerve cell growth than control animals," study first author Shinsuke Ishigaki says. "Crucially, the mice showed increased levels of a modified form of tau that is a known hallmark of FTLD and other neurodegenerative diseases."
The team attempted to rescue this disease phenotype in mice by rebalancing the 4R-T/3R-T ratio. "We achieved this by introducing a short sequence of RNA to block 4R-T expression," corresponding author Gen Sobue explains. "This recovered most of the changes associated with FTLD that had been caused by FUS or SFPQ silencing."
The researchers confirmed that the link between FUS/SFPQ and tau isoform regulation also exists in humans using a model from human stem cell-derived neurons and a mini-gene, implying a role for tau isoform imbalance in FTLD development in humans.
True, but being that he is on a panel, whats the chances of having something materialistic to present?
IMO, it'll show how Missling is up to date with his company and how the 21 Century Cures Act will help benefit his company towards getting approval. He may say things generally speaking, but it'll undoubtedly pertain to Anavex.
We dont need another PR. The Dr. talks tomorrow and Park West 13G not to mention closing above $6 should keep us in the chatter for a day or two. Glad I sold my kb_f and moved profits back to here.
No blu_1, you didn't just hypothesize a simple reasoning behind our super 6, did you?
When that time comes yes. The DR is in the drivers seat and just drove us through some stormy weather. He's a smart driver and one that has repeatedly said we will pick up a hitch hiker when the time comes. The hitched will help us get to our destination since he knows the fastest route to where we are going.
Come on, efficacy never happened in any BP trial. IF it was anything else, wouldn't it have happened in other trials?
I'm basically interpreting your thought as "Don't invest yet, let the hedges and the instys first since they know more than the common investor. Then once it's priced out of reach and every other analyst gives the green light, that's when you invest." Oh yeah, then it will be proven that a2-73 was the reason.
RIGHT, I'll quote the DR. We are not afraid to think differently.
Anyone know what crypto coin they bought?
We have another ~800k shares held by 8 new tutes filed on the 9th and 10th.
Thinking out loud here, but Anavex could sure use BIIBs priority review voucher they have in their back pocket.
we keep OUR CEO and now we are talking. Lol
Having A-273 work really good for some and supposedly not others is way better than what the current soc is, which is not that better than placebo itself. You do understand that patients have a say in the 21 century cures act and seems like our patients are singing like birds. Any other patients you know of that are in AD trials that have that positive an attitude?
Because time and time again the stock market proves it is a machine that transfers money from the impatient to the patient. Imagine how many of us on this board will sell way too early and miss the most epic reward of all.
Great day today. My calls sold +50%. Too chicken to let it ride out till next week for possibly more. It COULD have "whip sawed" back down and expired worthless.
RESEARCH FEED
February 6, 2017 - AVXL
Targeting the Sigma-1 Receptor to Treat Neurological Diseases
Could this be the reason? Looks like its 2 hours old
https://twitter.com/NobleFinancial
#AVXL Targeting the Sigma-1 Receptor to Treat Neurological Diseases http://bit.ly/2kfaMBw #NOBLEFCM
Jimmy, if you got to Anavex twitter and see who they are following, they have some government accounts and a lot of Wall Street journal journalists, then there's AF as seen in the pic
http://imgur.com/Y7hmriR
I bet if history repeats itself in a p2/3 he would then shout it out for all to hear. Interesting that Anavex is following AF on twitter.
It was ISTSS 2015 conference. International Society for Traumatic Stress Studies
Here's the pic
http://imgur.com/8f0T8rM
I believe so. While Missling was presenting somewhere, she was attending a traumatic brain injury conference and the board was excited because she tweeted a pic from the conference.
Also, lets not forget our red headed employee attended a brain injury conference and even tweeted a pic. Can't seem to remember her name or when it was. Anyone else remember?
Let's see if the MM start playing with the pps as Feb options expire in 13 days, then off to March and April options as they seem to be pretty active now.
I actually found a heartbreaking story about dementia on fox today.
http://www.foxnews.com/health/2017/02/01/man-shares-moment-mom-battling-dementia-forgets-who-is.html
A son decided to document his time with his mom who has Lewy body dementia. Really makes one hope the FDA approves something for them to take soon. Cant imagine what it would feel like to have your mom not know that you are her son.
In a trial that enrolled 33 myelofibrosis patients, Geron's imetelstat generated a clinical response defined in part by an observed improvement on bone marrow damage among about 21% of patients. Furthermore, 12% experienced a complete remission defined by complete reversal of damage.
So now that he bashed Anavex for only having 32 patients in its trial, he's using Geron and its 33 patient trial? Furthermore, he goes on to talk about the result, 21% of patients showed improvement. WHAT WAS THAT % THAT SHOWED IMPROVEMENT FOR ALZHEIMER'S? Thats right, 2 or 3 times more patients than his example. Remission or not, Anavex will be alone in the biggest market available yet expects people to believe ACAD and Geron is a better bet? Have a bridge to sell with that explanation too?
Feb. 2017, Volume 25, Issue Number 2
http://www.mdedge.com/neurologyreviews/issues
New article?
I don't THINK I read it before.
http://www.mdedge.com/neurologyreviews/article/130412/alzheimers-cognition/can-sigma-1-agonist-stabilize-cognition-and
He did say that a Clinical Confirmation P2 placebo controlled trial for Parkinson's is in 2017 too right? I mean, its right there in the slide. How can they possibly run 3 trials, more importantly, where is the money coming from? Great question as we found out where our Rett trial $$ is a collaboration with Rettfoundation. Can't wait for this year to move along. Exciting times ahead.
Slide
He also said the following:
The president said that "competition is the key to lower drug prices," and he promised to "oppose anything that makes it harder for smaller, younger drug companies to take the risk" of bringing a medication to market.
Tutes are starting to show interest. Russell Investments Group just filed their 13F which shows they have 25486 shares worth $102K. Im sure more will follow towards the end of the quarter.
Same can be said about hundreds of other clinical trials, but did any reversal happen there? Time better spent if things like that were posted on STwits.
I happened to take a screenshot of it back when it was accessible. Here it is
http://imgur.com/mzk8eeD
He's delivering perfectly fine for me. I'm in no rush to let go of my shares. If one wants quick profits, go look for a p&d stock.